[Commentary on] Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: An intergroup study of the Gynecology Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group Journal Article

  


Author: Daud, A.
Article Title: [Commentary on] Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: An intergroup study of the Gynecology Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
Keywords: cisplatin -- therapeutic use; paclitaxel -- adverse effects; carboplatin -- adverse effects; carboplatin -- therapeutic use; cisplatin -- adverse effects; ovarian neoplasms -- drug therapy; ovarian neoplasms -- mortality; administration, intraperitoneal; paclitaxel -- therapeutic use; administration, intravenous
Journal Title: Women's Oncology Review
Volume: 1
Issue: 1
ISSN: 1473-3404
Publisher: Taylor & Francis Group  
Date Published: 2001-03-01
Start Page: 64
End Page: 65
Language: English
ACCESSION: 2004135390
PROVIDER: EBSCOhost
PROVIDER: cin20
DOI/URL:

http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=2004135390&site=ehost-live
Notes: Accession Number: 2004135390 -- Entry Date: 20040813 -- Revision Date: 20090313 -- Publication Type: journal article; abstract; commentary -- Original Study: Markman M, Bundy B, Alberts D, Fowler J, Clark-Pearson D, Carson LF et al -- Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the Gynecology Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group -- J CLIN ONCOL 2001; 19: 1001-7 -- Journal Subset: Biomedical; Editorial Board Reviewed; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 101128014. -- Source: cin20